SMASh: A drug-inducible protein turnover control system

This drug-inducible and reversible protein degradation system is of particular interest to model-targeted protein degradation therapeutic approaches in the preclinical stage.

SMASh (Small-Molecule-Assisted Shutoff) degron system was developed and optimized to allow targeted and time-controlled degradation of a protein of interest. It was built as a self-cleaving degron that can be stabilized upon drug treatment (Chung HK et al. Nat Chem Biol 2015).

This drug-inducible and reversible protein degradation system is of particular interest to model-targeted protein degradation therapeutic approaches in preclinical stages (learn more: Targeted Protein Degradation: New Promises for "Undruggable" Diseases). It can also be used to create targeted inducible and reversible knock-out and knock-down systems.

SMASh does not need to be coupled to any other reagent to function; a single genetic modification allows for the development of an inducible and reversible targeted protein degradation system.

Access to a new innovative technology for targeted time-controlled protein degradation

The SMASh degron system was developed and first described in 2015 (Chung HK et al. Nat Chem Biol 2015 and US62/186,339). It has been shown to be functional in yeast, virus, and mammalian cells, and has been used in drug discovery (Rago et al. Biochem Biophys Res Commun 2019).

How it works

Without the drug, the SMASh tag self-cleaved from the protein of interest and is then degraded, with an unchanged level of expression of the protein of interest.

With the drug (in green), the SMASh-tag is stabilized and so, does not self-cleave, allowing for targeted degradation of the protein of interest.

Key references

Rago F, DiMare MT, Elliott G, Ruddy DA, Sovath S, Kerr G, Bhang HC, Jagani Z. Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers. Biochem Biophys Res Commun. 2019 Jan 1;508(1):109–116.

Chung HK, Jacobs CL, Huo Y, Yang J, Krumm SA, Plemper RK, Tsien RY, Lin MZ. Tunable and reversible drug control of protein production via a self-excising degron. Nat Chem Biol. 2015 Sep;11(9):713–20.

genOway licenses secure your discoveries and research

genOway holds an exclusive license on SMASh for all uses in research tools.

You, the customer, are granted a permanent license under all technologies employed to create the model. This guarantees you its use for any and all relevant R&D purposes.

You also retain ownership of the deliverables and can patent the model developed. genOway has no claim on the results generated using the model we provide to you.

Other technologies

RMCE: Recombinase-Mediated Cassette Exchange

Recombinase-mediated cassette exchange enables the swapping of large genomic regions and is recommended for the generation of humanized models.

Learn more

FLEx: Reference technology for inducible point mutations

The FLEx technology is gold standard for inducible point mutations leading to kinase-dead and functional Knockouts, in a temporal- and tissue-specific manner.

Learn more

SSR: Site-Specific Recombination

Site-specific recombination is a gene engineering tool (e.g., Cre-lox and FLP-FRT systems) that relies on recombinases to replace specific DNA sequences.

Learn more

TET System: Controlled gene expression

Use tetracycline for reversible and efficient spatiotemporal control of gene expression. This on-demand gene induction mimics disease onset and progression.

Learn more

Homologous Recombination

Homologous recombination: A robust and efficient gene targeting technology for humanized, Knockin & conditional Knockout models for human disease studies.

Learn more

IRES: Internal ribosome entry site

IRES allows to co-express of several genes under the control of the same promoter and is considered to be the "go-to" technology for transgene co-expressions.

Learn more

CRISPR/Cas9 gene editing

CRISPR/Cas9: structure, mechanisms of action, efficacy, off-target activity, genetic backgrounds, multi-targeting, point-mutations, and large deletions.

Learn more